7 results match your criteria: "Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases[Affiliation]"
1-phenyl-3-methyl-5-pyrazolone activates the AMPK pathway to alleviate western-diet induced metabolic dysfunction-associated steatohepatitis in mice.
Clin Nutr
January 2025
Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China; Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, China; Key Speciality of Infection in Fujian Province, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China. Electronic address:
Background & Aims: Approved drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) are limited, although it has become the most common chronic liver disease worldwide. 1-phenyl-3-methyl-5-pyrazolone (PMP) possesses various biological effects such as anti-inflammatory and antioxidant. However, the effects and underlying mechanism of PMP in MASH remain unclear.
View Article and Find Full Text PDFThe prognostic role of diet quality in patients with MAFLD and physical activity: data from NHANES.
Nutr Diabetes
February 2024
Department of Hepatology, Hepatology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Background And Objectives: Dietary control and increased physical activity (PA) are recommended for patients with metabolic (dysfunction-) associated fatty liver disease (MAFLD). However, not all patients can sustain both exercise and a healthy diet. This study explored the interaction between dietary quality, PA levels, and mortality in MAFLD patients.
View Article and Find Full Text PDFInvestigating the shared genetic architecture between primary sclerosing cholangitis and inflammatory bowel diseases: a Mendelian randomization study.
BMC Gastroenterol
February 2024
Department of Hepatology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Article Synopsis
- The study investigates the potential causal relationship between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), particularly focusing on ulcerative colitis (UC) and Crohn's disease (CD).
- It uses Mendelian Randomization and genetic variants to analyze the effects of genetically predicted PSC on the risk of developing IBD, identifying a significant link to UC but not to CD.
- The findings highlight a causal association between genetically predicted PSC and UC, while calling for more research to explore shared genetic factors and underlying mechanisms connecting PSC and IBD.
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure.
Expert Rev Gastroenterol Hepatol
March 2024
Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Fuzhou, Fujian Province, China.
Article Synopsis
- This study examines the impact of metabolic-associated fatty liver disease (MAFLD) on patients with acute-on-chronic liver failure (ACLF) to determine its effects on patient prognosis.
- The research analyzed data from 339 patients over nearly nine years and found that those with MAFLD had a significantly lower survival rate and a higher incidence of complications compared to those without MAFLD.
- A new prognostic model, the TIM2 model, was developed, showing high accuracy in predicting mortality rates for patients with HBV-related ACLF.
[Analysis and prediction of burden of viral hepatitis C-associated diseases in China from 1990 to 2044].
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi
December 2023
Department of Hepatology, The First Affiliated Hospital, Fujian Medical University, Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Fuzhou, Fujian 350005, China.
Objective: To measure the burden of hepatitis C-associated diseases in China from 1990 to 2019, and to predict its changes from 2020 to 2044, so as to provide insights into formulation of the targeted hepatitis C control strategy.
Methods: The total burden due to hepatitis C-associated diseases in China from 1990 to 2019 were extracted from the Global Burden of Disease 2019 (GBD 2019) data resources, and the trends in age-standardized prevalence, incidence, mortality and disability-adjusted life years (DALYs) rate of hepatitis C-associated acute hepatitis C (AHC), chronic liver diseases (CLD) and liver cancer in China from 1990 to 2019 were evaluated in China from 1990 to 2019 using estimated annual percentage change (EAPC). In addition, the changes in the burden of hepatitis C-associated diseases were predicted in China from 2020 to 2044 using a Bayesian model.
[Burden of hepatitis B-associated diseases in China from 1990 to 2030].
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi
November 2023
Department of Hepatology, the First Affiliated Hospital of Fujian Medical University; Hepatology Research Institute, Fujian Medical University; Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Fuzhou, Fujian 350005, China.
Objective: To measure the burden of hepatitis B-associated diseases in China from 1990 to 2019, and to predict its changes from 2020 to 2030.
Methods: The age-standardized prevalence, incidence, mortality and disability-adjusted life years (DALY) rate of hepatitis B-associated diseases in China from 1990 to 2019 were extracted from the Global Burden of Disease 2019 (GBD 2019) data resources, and the trends in burdens of hepatitis B-associated diseases were evaluated from 1990 to 2019 using estimated annual percentage change (EAPC) and annual percent change (APC). In addition, the changes in the burden of hepatitis B-associated diseases were predicted in China from 2020 to 2023 using the Bayesian model.
Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients.
World J Hepatol
August 2023
Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Fuzhou 350005, Fujian Province, China.
Background: Tenofovir alafenamide (TAF) has a serum lipid-raising effect in patients with HIV; however, its effect on serum lipids and nonalcoholic fatty liver disease (NAFLD) risk in patients with chronic hepatitis B CHB) is unclear.
Aim: To compare the effects of TAF and entecavir (ETV) on serum lipid levels in patients with CHB.
Methods: In this retrospective cohort study, the data including the clinical features, serum lipids, and metabolic factors of patients with CHB at baseline and approximately 1 year after TAF or ETV treatment were collected and analyzed.